DSPE-PEG2000-Maleimide sodium (purity>95%)

Cat. No.: HY-140739 Purity: 94.97%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

DSPE-PEG2000-Maleimide sodium (purity>95%) is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide sodium (purity>95%) can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration.

For research use only. We do not sell to patients.

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of DSPE-PEG2000-Maleimide sodium (purity>95%):

DSPE-PEG5000-Maleimide In-stock
DSPE-PEG2000-Mal ammonium In-stock
DSPE-PEG2000-Maleimide free acid Get quote

2 Publications Citing Use of MCE DSPE-PEG2000-Maleimide sodium (purity>95%)

Bio/Physico-chemical Assay

: DSPE-PEG2000-Maleimide sodium (purity>95%) purchased from MedChemExpress. Usage Cited in: Compos B Eng. 2023 Oct 15, 111047.; The verification of DSPE-PEG2000-MAL-Cys-SDSSD by MALDI-TOF was performed. For the construction of BT-LGG-EVs, 1 mol Cys-SDSSD and 1 mol DSPE-PEG2000-Mal ammonium were mixed and allowed to react for 24 h to develop bone-targeting peptide DSPE-PEG-Mal-Cys-SDSSD.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	DSPE-PEG2000-Maleimide sodium (purity>95%) is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide sodium (purity>95%) can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration^[1]^[2]^[3]^[4].
In Vitro	DSPE-PEG2000-Maleimide sodium (purity>95%) is used to prepare targeted liposomes (TLPD)^[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. DSPE-PEG2000-Maleimide sodium (purity>95%) Related Antibodies
Molecular Weight	2000 (average)
Appearance	Solid
Color	White to off-white
SMILES	CCCCCCCCCCCCCCCCCC(O[C@](COP(OCCNC(OCCOCCNC(CCN1C(C=CC1=O)=O)=O)=O)(O[Na])=O)([H])COC(CCCCCCCCCCCCCCCCC)=O)=O.[n]
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	-20°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility	In Vitro: DMF : 50 mg/mL (Need ultrasonic) DMSO : 12.5 mg/mL (ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Molarity Calculator Dilution Calculator Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Mass = Concentration × Volume × Molecular Weight * Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final) This equation is commonly abbreviated as: C₁V₁ = C₂V₂ Concentration _(start) C1 × Volume _(start) V1 = Concentration _(final) C2 × Volume _(final) V2 In Vivo: Select the appropriate dissolution method based on your experimental animal and administration route. For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents: To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day. The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution. Protocol 1 Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline Solubility: ≥ 1.25 mg/mL; Clear solution This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL. Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution. Protocol 2 Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline) Solubility: ≥ 1.25 mg/mL; Clear solution This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear. Protocol 3 Add each solvent one by one: 10% DMSO 90% Corn Oil Solubility: ≥ 1.25 mg/mL; Clear solution This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully. Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly. In Vivo Dissolution Calculator Please enter the basic information of animal experiments: Dosage mg/kg Animal weight (per animal) g Dosing volume (per animal) μL Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments. Please enter your animal formula composition: % DMSO + % + % Tween-80 + % Saline Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak. The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE). Calculation results: Working solution concentration: mg/mL Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL). In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE). Tel: 609-228-6898 E-mail: [email protected] Technical Support: [email protected] Method for preparing in vivo working solution for animal experiments:* Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline. Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution If the continuous dosing period exceeds half a month, please choose this protocol carefully. Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation	Purity: 99.58% Select Batch: Data Sheet (269 KB) SDS (393 KB) COA (241 KB) HNMR (314 KB) CNMR (299 KB) RP-HPLC (252 KB) Handling Instructions (2659 KB)
References	[1]. Nallamothu R, et al. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies. PDA J Pharm Sci Technol. 2006;60(3):144-155. [Content Brief] [2]. Gao J, et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials. 2011;32(13):3459-3470. [Content Brief] [3]. Ishida T, et al. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 1999 Oct 22;460(1):129-33. [Content Brief] [4]. Herrera-Barrera M, et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci Adv. 2023 Jan 13;9(2):eadd4623. [Content Brief]